Restricted Mean Survival Time Analysis to Estimate SGLT2i–Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.46928
Abstract: Key Points Question Is restricted mean survival time (RMST) analysis feasible to translate comparative cardiovascular and kidney outcomes of sodium-glucose cotransporter-2 inhibitor (SGLT2i) vs dipeptidyl peptidase-4 inhibitor (DPP4i) therapy in routine clinical settings? Findings In… read more here.
Keywords: cardiorenal outcomes; restricted mean; analysis; mean survival ... See more keywords
Cardiorenal outcomes in eligible patients referred for bariatric surgery
Sign Up to like & getrecommendations! Published in 2021 at "Obesity"
DOI: 10.1002/oby.23294
Abstract: Bariatric surgery is associated with reduced atherosclerotic cardiovascular disease (CVD) and heart failure hospitalization in people with type 2 diabetes (T2D) and those with prior CVD. Most patients undergoing bariatric surgery do not have T2D… read more here.
Keywords: surgery; outcomes eligible; bariatric surgery; cardiorenal outcomes ... See more keywords
GLP‐1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta‐analysis including the REWIND and PIONEER 6 trials
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes"
DOI: 10.1111/dom.13847
Abstract: A meta‐analysis of cardiovascular outcome trials (CVOTs) comparing glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and placebo concerning cardiorenal outcomes in patients with type 2 diabetes (T2D) is presented. An electronic search without language restrictions up to… read more here.
Keywords: analysis; receptor agonists; type diabetes; cardiorenal outcomes ... See more keywords
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes"
DOI: 10.1111/dom.14670
Abstract: Empagliflozin treatment reduced liver fat in small type 2 diabetes cohorts. This post‐hoc study evaluated effects of empagliflozin on risk for non‐alcoholic fatty liver disease‐related steatosis and fibrosis, as well as the relationship between risk… read more here.
Keywords: empagliflozin markers; relationship; cardiorenal outcomes; steatosis fibrosis ... See more keywords
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes"
DOI: 10.1111/dom.14923
Abstract: To conduct a post hoc analysis to explore indices of hepatic steatosis/fibrosis and cardiorenal outcomes in the VERTIS CV study. read more here.
Keywords: cardiorenal outcomes; steatosis fibrosis; liver steatosis; indices liver ... See more keywords
Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial
Sign Up to like & getrecommendations! Published in 2022 at "Circulation"
DOI: 10.1161/circulationaha.121.058294
Abstract: © 2022 The Authors. Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs… read more here.
Keywords: ertugliflozin baseline; cardiorenal outcomes; baseline metformin; outcomes ertugliflozin ... See more keywords